Cancer Res Treat.  2012 Mar;44(1):32-36.

Prognostic Impact of Polymorphisms in the CASPASE Genes on Survival of Patients with Colorectal Cancer

• Choi JY
• Kim JG
• Lee YJ
• Chae YS
• Sohn SK
• Moon JH
• Kang BW
• Jung MK
• Jeon SW
• Park JS
• Choi GS

Abstract

PURPOSE
This study analyzed potentially functional polymorphisms in CASPASE (CASP) genes and their impact on the prognosis for Korean colorectal cancer patients.
MATERIALS AND METHODS
A total of 397 consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in this study. Genomic DNA from these patients was extracted from fresh colorectal tissue, and the 10 polymorphisms in the CASP3, CASP6, CASP7, CASP8, CASP9, and CASP10 genes were determined using a reverse transcription polymerase chain reaction genotyping assay.
RESULTS
The median patient age was 63 years, and 218 (54.9%) patients had colon cancer, while 179 (45.1%) patients had rectal cancer. Univariate and multivariate survival analysis including pathologic stage, patient age, differentiation, and carcinoembryonic antigen level demonstrated that these polymorphisms were not associated with either disease-free or overall survival.
CONCLUSION
None of the 10 polymorphisms in the CASP genes investigated in this study was found to be an independent prognostic marker for Korean patients with curatively resected colorectal cancer.

Keyword

Colorectal neoplasms; Caspases; Genetic polymorphism; Prognosis

MeSH Terms

Adenocarcinoma
Carcinoembryonic Antigen
Caspase 3
Caspases
Colonic Neoplasms
Colorectal Neoplasms
DNA
Humans
Polymerase Chain Reaction
Polymorphism, Genetic
Prognosis
Rectal Neoplasms
Reverse Transcription
Carcinoembryonic Antigen
Caspase 3
Caspases
DNA

Reference

1. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23:609–618. PMID: 15659508.

2. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000; 157:1415–1430. PMID: 11073801.

3. Nagata S. Apoptosis by death factor. Cell. 1997; 88:355–365. PMID: 9039262.

4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000; 21:485–495. PMID: 10688869.

5. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411:342–348. PMID: 11357141.

6. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem. 2003; 88:885–898. PMID: 12616528.

7. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997; 22:299–306. PMID: 9270303.

8. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999; 15:269–290. PMID: 10611963.

9. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003; 22:8543–8567. PMID: 14634618.

10. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004; 384(Pt 2):201–232. PMID: 15450003.

11. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007; 39:605–613. PMID: 17450141.

12. Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006; 15:1963–1971. PMID: 16687442.

13. Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, et al. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog. 2008; 47:383–390. PMID: 18058802.

14. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004; 96:1866–1869. PMID: 15601643.

15. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, et al. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008; 29:1443–1451. PMID: 18563783.

16. Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, Schmutzler RK, et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis. 2006; 27:606–609. PMID: 16251207.

17. Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, Kim MJ, et al. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2009; 27:5823–5829. PMID: 19826114.

18. Hamilton SR, Aaltonen LA. World Health Oorganization classification of tumors. Pathology and genetics: tumours of the digestive system. 2000. Lyon: IARC Press.

19. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 2002. 6th ed. New York: Springer-Verlag.

20. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006; 34(Web Server issue):W635–W641. PMID: 16845089.

21. Son JW, Kang HK, Chae MH, Choi JE, Park JM, Lee WK, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet. 2006; 169:121–127. PMID: 16938569.

22. Liu B, Zhang Y, Jin M, Ni Q, Liang X, Ma X, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010; 49:75–84. PMID: 19795398.

23. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol. 2009; 64:953–960. PMID: 19219602.

24. Chae YS, Kim JG, Sohn SK, Lee SJ, Kang BW, Moon JH, et al. RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection. J Cancer Res Clin Oncol. 2011; 137:705–713. PMID: 20567846.